ChimeriVax-West Nile virus live-attenuated vaccine

Preclinical evaluation of safety, immunogenicity, and efficacy

Juan Arroyo, Chuck Miller, John Catalan, Gwendolyn A. Myers, Marion S. Ratterree, Dennis W. Trent, Thomas P. Monath

Research output: Contribution to journalArticle

135 Citations (Scopus)

Abstract

The availability of ChimeriVax vaccine technology for delivery of flavivirus protective antigens at the time West Nile (WN) virus was first detected im North America in 1999 contributed to the rapid development of the vaccine candidate against WN virus described here. ChimeriVax-Japanese encephalitis (JE), the first live-attenuated vaccine developed with this technology has successfully undergone phase I and II clinical trials. The ChimeriVax technology utilizes yellow fever virus (YF) 17D vaccine strain capsid and nonstractural genes to deliver the envelope gene of other flaviviruses as live-attenuated chimeric viruses. Amino acid sequence homology between the envelope protein (E) of JE and WN viruses facilitated targeting attenuating mutation sites to develop the WN vaccine. Here we discuss preclinical studies with the ChimeriVax-WN virus in mice and macaques. ChimeriVax-WN virus vaccine is less neurovirulent than the commercial YF 17D vaccine in mice and nonhuman primates. Attenuation of the virus is determined by the chimeric nature of the construct containing attenuating mutations in the YF 17D virus backbone and three point mutations introduced to alter residues 107, 316, and 440 in the WN virus E protein gene. The safety, immunogenicity, and efficacy of the ChimeriVax-WN02 vaccine in the macaque model indicate the vaccine candidate is expected to be safe and immunogenic for humans.

Original languageEnglish (US)
Pages (from-to)12497-12507
Number of pages11
JournalJournal of Virology
Volume78
Issue number22
DOIs
StatePublished - Nov 2004

Fingerprint

West Nile virus
Attenuated Vaccines
live vaccines
Vaccines
immune response
vaccines
Safety
Yellow fever virus
Japanese Encephalitis
Flavivirus
Macaca
encephalitis
Viruses
Technology
viruses
West Nile Virus Vaccines
Flaviviridae
mutation
Amino Acid Sequence Homology
Phase II Clinical Trials

ASJC Scopus subject areas

  • Immunology

Cite this

Arroyo, J., Miller, C., Catalan, J., Myers, G. A., Ratterree, M. S., Trent, D. W., & Monath, T. P. (2004). ChimeriVax-West Nile virus live-attenuated vaccine: Preclinical evaluation of safety, immunogenicity, and efficacy. Journal of Virology, 78(22), 12497-12507. https://doi.org/10.1128/JVI.78.22.12497-12507.2004

ChimeriVax-West Nile virus live-attenuated vaccine : Preclinical evaluation of safety, immunogenicity, and efficacy. / Arroyo, Juan; Miller, Chuck; Catalan, John; Myers, Gwendolyn A.; Ratterree, Marion S.; Trent, Dennis W.; Monath, Thomas P.

In: Journal of Virology, Vol. 78, No. 22, 11.2004, p. 12497-12507.

Research output: Contribution to journalArticle

Arroyo, J, Miller, C, Catalan, J, Myers, GA, Ratterree, MS, Trent, DW & Monath, TP 2004, 'ChimeriVax-West Nile virus live-attenuated vaccine: Preclinical evaluation of safety, immunogenicity, and efficacy', Journal of Virology, vol. 78, no. 22, pp. 12497-12507. https://doi.org/10.1128/JVI.78.22.12497-12507.2004
Arroyo, Juan ; Miller, Chuck ; Catalan, John ; Myers, Gwendolyn A. ; Ratterree, Marion S. ; Trent, Dennis W. ; Monath, Thomas P. / ChimeriVax-West Nile virus live-attenuated vaccine : Preclinical evaluation of safety, immunogenicity, and efficacy. In: Journal of Virology. 2004 ; Vol. 78, No. 22. pp. 12497-12507.
@article{c7d58c752c25498dbf648768b68b44b6,
title = "ChimeriVax-West Nile virus live-attenuated vaccine: Preclinical evaluation of safety, immunogenicity, and efficacy",
abstract = "The availability of ChimeriVax vaccine technology for delivery of flavivirus protective antigens at the time West Nile (WN) virus was first detected im North America in 1999 contributed to the rapid development of the vaccine candidate against WN virus described here. ChimeriVax-Japanese encephalitis (JE), the first live-attenuated vaccine developed with this technology has successfully undergone phase I and II clinical trials. The ChimeriVax technology utilizes yellow fever virus (YF) 17D vaccine strain capsid and nonstractural genes to deliver the envelope gene of other flaviviruses as live-attenuated chimeric viruses. Amino acid sequence homology between the envelope protein (E) of JE and WN viruses facilitated targeting attenuating mutation sites to develop the WN vaccine. Here we discuss preclinical studies with the ChimeriVax-WN virus in mice and macaques. ChimeriVax-WN virus vaccine is less neurovirulent than the commercial YF 17D vaccine in mice and nonhuman primates. Attenuation of the virus is determined by the chimeric nature of the construct containing attenuating mutations in the YF 17D virus backbone and three point mutations introduced to alter residues 107, 316, and 440 in the WN virus E protein gene. The safety, immunogenicity, and efficacy of the ChimeriVax-WN02 vaccine in the macaque model indicate the vaccine candidate is expected to be safe and immunogenic for humans.",
author = "Juan Arroyo and Chuck Miller and John Catalan and Myers, {Gwendolyn A.} and Ratterree, {Marion S.} and Trent, {Dennis W.} and Monath, {Thomas P.}",
year = "2004",
month = "11",
doi = "10.1128/JVI.78.22.12497-12507.2004",
language = "English (US)",
volume = "78",
pages = "12497--12507",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "22",

}

TY - JOUR

T1 - ChimeriVax-West Nile virus live-attenuated vaccine

T2 - Preclinical evaluation of safety, immunogenicity, and efficacy

AU - Arroyo, Juan

AU - Miller, Chuck

AU - Catalan, John

AU - Myers, Gwendolyn A.

AU - Ratterree, Marion S.

AU - Trent, Dennis W.

AU - Monath, Thomas P.

PY - 2004/11

Y1 - 2004/11

N2 - The availability of ChimeriVax vaccine technology for delivery of flavivirus protective antigens at the time West Nile (WN) virus was first detected im North America in 1999 contributed to the rapid development of the vaccine candidate against WN virus described here. ChimeriVax-Japanese encephalitis (JE), the first live-attenuated vaccine developed with this technology has successfully undergone phase I and II clinical trials. The ChimeriVax technology utilizes yellow fever virus (YF) 17D vaccine strain capsid and nonstractural genes to deliver the envelope gene of other flaviviruses as live-attenuated chimeric viruses. Amino acid sequence homology between the envelope protein (E) of JE and WN viruses facilitated targeting attenuating mutation sites to develop the WN vaccine. Here we discuss preclinical studies with the ChimeriVax-WN virus in mice and macaques. ChimeriVax-WN virus vaccine is less neurovirulent than the commercial YF 17D vaccine in mice and nonhuman primates. Attenuation of the virus is determined by the chimeric nature of the construct containing attenuating mutations in the YF 17D virus backbone and three point mutations introduced to alter residues 107, 316, and 440 in the WN virus E protein gene. The safety, immunogenicity, and efficacy of the ChimeriVax-WN02 vaccine in the macaque model indicate the vaccine candidate is expected to be safe and immunogenic for humans.

AB - The availability of ChimeriVax vaccine technology for delivery of flavivirus protective antigens at the time West Nile (WN) virus was first detected im North America in 1999 contributed to the rapid development of the vaccine candidate against WN virus described here. ChimeriVax-Japanese encephalitis (JE), the first live-attenuated vaccine developed with this technology has successfully undergone phase I and II clinical trials. The ChimeriVax technology utilizes yellow fever virus (YF) 17D vaccine strain capsid and nonstractural genes to deliver the envelope gene of other flaviviruses as live-attenuated chimeric viruses. Amino acid sequence homology between the envelope protein (E) of JE and WN viruses facilitated targeting attenuating mutation sites to develop the WN vaccine. Here we discuss preclinical studies with the ChimeriVax-WN virus in mice and macaques. ChimeriVax-WN virus vaccine is less neurovirulent than the commercial YF 17D vaccine in mice and nonhuman primates. Attenuation of the virus is determined by the chimeric nature of the construct containing attenuating mutations in the YF 17D virus backbone and three point mutations introduced to alter residues 107, 316, and 440 in the WN virus E protein gene. The safety, immunogenicity, and efficacy of the ChimeriVax-WN02 vaccine in the macaque model indicate the vaccine candidate is expected to be safe and immunogenic for humans.

UR - http://www.scopus.com/inward/record.url?scp=7644241258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7644241258&partnerID=8YFLogxK

U2 - 10.1128/JVI.78.22.12497-12507.2004

DO - 10.1128/JVI.78.22.12497-12507.2004

M3 - Article

VL - 78

SP - 12497

EP - 12507

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 22

ER -